E. A. Kondrasheva

E. A. Kondrasheva

Auto-generated profile, based on publicly available information

E. A. Kondrasheva

OOO Invitro-Moscow

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2022 in Russian Clinical Laboratory Diagnostics
Verified
Journal Article
Open access
DSDar’jA Vladimirovna Sidorenko
Dar’jA Vladimirovna Sidorenko
VNVladimir Nazarov
Vladimir Nazarov
EVE. G. Volnikova
E. G. Volnikova
EKE. A. Kondrasheva
E. A. Kondrasheva
NPN. G. Peshkova
N. G. Peshkova
SLSergey V. Lapin
Sergey V. Lapin
Diagnosis of Gilbert’s syndrome is based on the detection of homozygous carriage of an additional TA-repeat in the promoter of the UGT1A1 gene, leading to a decrease in the activity of the UGT enzyme. No large studies have been done in the Russian Federation on the prevalence of carriage of Gilbert’s syndrome, as well as the biochemical and molecular profile of such patients. The aim of the study is to evaluate biochemical and molecular genetic parameters in patients with Gilbert’s syndrome in Russia. The study included 124 healthy volunteers (group 1) and 5650 patients with suspected Gilbert’s syndrome (group 2). The number of TA-repeats of the promoter region of the UGT1A1 gene was determined by the method of fragment analysis for all participants. The following biochemical parameters were analyzed for 299 patients from group 2: the level of bilirubin and its fractions, AST, ALT, cholesterol and LDL. In group 1 the prevalence of genotype (TA)6/(TA)6 was 39,52%, (TA)6/(TA)7 - 53,23%, (TA)7/(TA)7 - 7,26%, no rare forms were found. In group 2 the prevalence of genotype (TA)6/(TA)6 was 6,04%, (TA)6/(TA)7 - 20,05%, (TA)7/(TA)7 - 73,7%, rare alleles - 0,2%. Rare alleles included (TA)5/(TA)6, (TA)5/(TA)7, (TA)6/(TA)8 and (TA)7/(TA)8, as well as a new genotype not described in the literature previously - (TA)7/(TA)9. When assessing the level of total bilirubin and its fractions, a difference was revealed between the genotype of Gilbert’s syndrome (TA)7/(TA)7 and the reference genotype (TA)6/(TA)6, and between genotypes (TA)7/(TA)7 and (TA)6/(TA)7. A significant increase in total bilirubin was demonstrated in carriers of a larger number of TA-repeats. There was no significant difference in the concentration of ALT, AST, cholesterol or LDL between different genotypes.The number of TA-repeats of the UGT1A1 gene affects the increase of total bilirubin and its indirect fraction, including the cases of rare allelic variants (TA≤5, TA≥8), but not the activity of ALT and AST and the lipid profile.

11 March 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
AKA.N. Khannanova
A.N. Khannanova
LBL.V. Brylev
L.V. Brylev
APA.A. Prusova
A.A. Prusova
EAE.V. Aksenova
E.V. Aksenova
EKE.A. Kondrasheva
E.A. Kondrasheva
IKI.S. Kovaleva
I.S. Kovaleva
Autoimmune encephalitis is a group of diseases researched by both neurologists and psychiatrists. Despite a large number of studies and practical recommendations, the differential diagnosis and early diagnostics still remains an important issue. The most difficult to diagnose are cases that debut as mental disorders and/or occur without neurological symptoms. The literature review presents the current state of the problem with an emphasis on the practice of a psychiatrist.

1 January 2025 in Immunologiya
Verified
Journal Article
Open access
OSO.V. Sebekina
O.V. Sebekina
NNN.M. Nenasheva
N.M. Nenasheva
EKE.A. Kondrasheva
E.A. Kondrasheva
MIMoscow Limited Liability Company «Independent Laboratory Invitro»
Moscow Limited Liability Company «Independent Laboratory Invitro»
OLO.F. Li
O.F. Li
SSSt. Petersburg Limited Liability Company «Invitro Spb»
St. Petersburg Limited Liability Company «Invitro Spb»
Оценка профиля сенсибилизации к аллергенным молекулам семейства тропомиозинов у пациентов Московского региона

4 December 2024 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
PBP. O. Bogomolov
P. O. Bogomolov
NSN. A. Shub
N. A. Shub
NGN. A. Gasilova
N. A. Gasilova
ABA. A. Belyakova
A. A. Belyakova
TLT. G. Lidzhieva
T. G. Lidzhieva
IMIgor V. Maev
Igor V. Maev
Aim: to evaluate the significance of a positive polymerase chain reaction result for hepatitis D virus RNA (HDV RNA) in liver biopsy specimens of patients with chronic hepatitis D (CHD) after completion of antiviral therapy (AVT) as a predictor of infection relapse.Materials and methods. The study included 21 patients with CHD who received combined AVT with peginterferon alpha and bulevirtide for 48 weeks, followed by bulevirtide monotherapy for 48–96 weeks, making the total duration of antiviral therapy 96–144 weeks. In all patients HDV RNA became undetectable in serum 24–96 weeks from the start of treatment, with aviremia maintained for at least 48 weeks until the end of AVT. At the end of treatment, all patients underwent liver biopsy to detect HDV RNA in liver tissue.Results. Out of 21 patients with sustained complete virological response (negative polymerase chain reaction result for HDV RNA in serum), 8 (38 %) had HDV RNA detected in liver tissue, indicating that a tissue virological response was not achieved. All 8 patients experienced a relapse of CHD within 24 weeks after discontinuing AVT.Conclusions. In patients with chronic hepatitis D who have achieved a complete virological response in serum, the absence of a virological response in liver tissue (detection of HDV RNA in liver biopsy) is a predictor of relapse, providing a rationale for the continuation of antiviral therapy.